RD can only be treated temporarily through hematopoietic stem cell transplantation (HSCT) and cytokine therapy. Hematopoietic stem cell transplantation Transplantation of stem cells are taken from the bone marrow, peripheral blood or umbilical cord of healthy, matched donors. Hematopoietic stem cell transplantation (HSCT) involves intravenous infusion of stem cells to those who have either a damaged bone marrow or defective immune system. Transplantation is a simple process. Bone marrow product is infused through a central vein over a period of several hours. The hematopoietic cells are able to go to the bone marrow through tracking mechanisms. Patients who suffer from RD will now have more stem cells that can differentiate into immune cells. Cytokine Therapy Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) can be used as a temporary cure. GM-CSF stimulates production of white blood cells. This cure is commonly used in patients who are awaiting bone marrow transplantation. Response to this cure can vary. Those with a more severe combined immunodeficiency may have no response to this therapy.
Reticular dysgenesis
Thymic hypoplasia
IgG deficiency
Thyroid dysgenesis
T cell deficiency
Leukocyte adhesion molecule deficiency
GATA2 deficiency
Adenosine deaminase deficiency